Abstract:Background: Regulating epithelial-to-mesenchymal transition (EMT) in cancer cells has been widely considered as an approach to combat cancer progression and therapeutic resistance, whereas a limited number of broadly comprehensive investigations of miRNAs involved in metastatic colorectal cancer (mCRC) have been conducted. In this study, we investigated the roles and mechanisms of EMT process in mCRC. Methods: We used ISH and RT-qPCR to measure expression of miR93 in CRC tissues, nontumor tissues and metastatic liver tissues. CRC cell lines were transduced with lentiviruses expressed miR93. Its inhibitor sequence targeted miR93 or a scrambled sequence (control). Proliferation, metastasis, invasion and colony formation and growth of CRC cells which overexpress miR93 or its inhibitor in severe combined immune-deficient mice were analysed. Western blot, and luciferase assays were used to measure expression of Eph tyrosine kinase receptor (EphA4) and related signalling molecules. Results: In this study, we demonstrated that miR93 regulated EMT process by targeting EphA4 in mCRC. CRC tissues and metastatic liver tissues had increased levels of miR93 compared with the nontumor tissues and cells, and miR93 can regulate EMT process. Overexpression of miR93 increased proliferation of CRC cells, metastasis, invasion and colony formation in vitro, whereas miR93 depletion reduced these parameters. In nude mice, overexpression of miR93 by CRC cells increased liver metastasis and overexpression of the miR93 inhibitor reduced it. Then we identified by microarray analysis that the direct and functional target genes of miR93 was EphA4. Knockdown of EphA4 phenocopied the effect of miR-93 and ectopic expression of EphA4 restored the effect of miR93 on proliferation, migration, invasion and liver metastasis in CRC cells. Conclusions: Our findings revealed miR93 regulates EMT process by targeting EphA4 to affect liver metastasis in CRC. miR93 inhibited tumor metastasis by directly targeting EphA4, a crucial factor in regulating EMT. Collectively, this study provides new insights into exploring the therapeutic potential of miR93, which is able to regulate EMT process to affect tumor metastasis, and warrant further study in clinical settings. Clinical trial indentification: The present study was supported in part by grants from the Health and Family Planning Commission of Shanxi Province (No.2015049), the Applied Basic Research Programs of Shanxi Science and Technology Department (No.201601D011128). Legal entity responsible for the study: The Health and Family Planning Commission of Shanxi Province, the Applied Basic Research Programs of Shanxi Science and Technology Department Funding: The Health and Family Planning Commission of Shanxi Province, the Applied Basic Research Programs of Shanxi Science and Technology Department Disclosure: All authors have declared no conflicts of interest.

Mir-93-5p Inhibits the Emt of Breast Cancer Cells Via Targeting Mkl-1 and Stat3

Mir-145 Suppresses Breast Cancer Cell Migration by Targeting FSCN-1 and Inhibiting Epithelial-Mesenchymal Transition.

Mir-145-5p Inhibits Epithelial-Mesenchymal Transition Via the JNK Signaling Pathway by Targeting MAP3K1 in Non-Small Cell Lung Cancer Cells.

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

miR-615-3p promotes the epithelial-mesenchymal transition and metastasis of breast cancer by targeting PICK1/TGFBRI axis

Mir-129-5p Attenuates Cell Proliferation and Epithelial Mesenchymal Transition Via HMGB1 in Gastric Cancer

Mir-93 Regulates Epithelial-to-mesenchymal Transition Process in Metastatic Colorectal Cancer by Targeting EphA4

Mir-142-5p Inhibits Cell Invasion and Migration by Targeting DNMT1 in Breast Cancer

Mir-503-3p Promotes Epithelialemesenchymal Transition in Breast Cancer by Directly Targeting Smad2 and E-Cadherin

Regulation of Cancerous Progression and Epithelial-Mesenchymal Transition by Mir-34C-3p Via Modulation of MAP3K2 Signaling in Triple-Negative Breast Cancer Cells.

Mir-125A-5p Suppresses Epithelial-Mesenchymal Transition Via GSK-3β/Snail Signaling Pathway in Breast Cancer Cells

Effects of miR‐93 on epithelial‐to‐mesenchymal transition and vasculogenic mimicry in triple‐negative breast cancer cells

Mir-219A-5p Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition by Targeting Myocardin-Related Transcription Factor A.

MicroRNA93 Regulates Proliferation and Differentiation of Normal and Malignant Breast Stem Cells

MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion

Mir-143-3p Targeting LIM Domain Kinase 1 Suppresses the Progression of Triple-Negative Breast Cancer Cells.

Mir-26a Inhibits Proliferation and Migration of Breast Cancer Through Repression of Mcl-1

Molecular mechanism of miR‐153 inhibiting migration, invasion and epithelial‐mesenchymal transition of breast cancer by regulating transforming growth factor beta (TGF‐β) signaling pathway

Methylation-mediated Silencing of Mir-133A-3p Promotes Breast Cancer Cell Migration and Stemness Via Mir-133A-3p/maml1/dnmt3a Positive Feedback Loop

Mir-296-5p Suppresses EMT of Hepatocellular Carcinoma Via Attenuating NRG1/ERBB2/ERBB3 Signaling

MiR-206 Suppresses Epithelial Mesenchymal Transition by Targeting TGF-β Signaling in Estrogen Receptor Positive Breast Cancer Cells